Related Experiment Video
Updated: Aug 24, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications
Hyesun Park1, Shu-Chi Tseng1, Lynette M Sholl1
1From the Departments of Radiology (H.P., S.C.T., H.H., M.N.), Pathology (L.M.S.), Medical Oncology (M.M.A.), and Medicine (M.M.A.), Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave, Boston, MA 02215.
Abstract:
Small cell lung cancer (SCLC) is a highly aggressive malignancy with exceptionally poor prognosis, comprising approximately 15% of lung cancers. Emerging knowledge of the molecular and genomic landscape of SCLC and recent successful clinical applications of new systemic agents have allowed for precision oncology treatment approaches. Imaging is essential for the diagnosis, staging, and treatment monitoring of patients with SCLC. The role of imaging is increasing with the approval of new treatment agents, including immune checkpoint inhibitors, which lead to novel imaging manifestations of response and toxicities. The purpose of this state-of-the-art review is to provide the reader with the latest information about SCLC, focusing on the subtyping of this malignancy (molecular characterization) and the emerging systemic therapeutic approaches and their implications for imaging. The review will also discuss the future directions of SCLC imaging, radiomics and machine learning.
Insights
Small cell lung cancer (SCLC) is aggressive, but new treatments and imaging offer hope. This review covers SCLC molecular subtypes, therapies, and advanced imaging techniques like radiomics for better patient outcomes.
Area of Science:
- Oncology
- Radiology
- Genomics
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis, accounting for ~15% of lung cancers.
- Advances in understanding SCLC's molecular and genomic landscape are driving precision oncology.
- Imaging is critical for SCLC diagnosis, staging, and monitoring treatment response.
Purpose of the Study:
- To provide a state-of-the-art review of SCLC.
- To focus on molecular subtyping and emerging systemic therapies.
- To discuss the implications of these advances for SCLC imaging.
Main Methods:
- Literature review of recent advancements in SCLC.
- Analysis of molecular and genomic data relevant to SCLC.
- Evaluation of current and emerging systemic therapeutic approaches.
- Assessment of novel imaging manifestations of treatment response and toxicities.
Main Results:
- New systemic agents and precision oncology approaches are improving SCLC treatment.
- Immune checkpoint inhibitors are leading to novel imaging findings.
- Molecular characterization is crucial for SCLC subtyping and targeted therapy.
Conclusions:
- Understanding SCLC molecular subtypes is key to personalized treatment.
- Advanced imaging techniques are essential for monitoring novel therapies and identifying treatment effects.
- Future directions include the integration of radiomics and machine learning in SCLC imaging.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
